ClinicalTrials.gg
Biological

23-valent pneumococcal capsular polysaccharide vaccine clinical trials

Also written PPV23 and Pneumo 23.

studies test it
39
open now
4
in phase 3
11
first study started
2000

How each study uses 23-valent pneumococcal capsular polysaccharide vaccine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the 23-valent pneumococcal capsular polysaccharide vaccine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

23-valent pneumococcal polysaccharide vaccine
7
Pneumovax
2

Development codes

PPV23
6
Pneumo 23
4

In one entry with another drug

Given together, or one or the other

Pneumovax 23
13
Prevenar® and Pneumo23®
2

Studies by the year they started

39 studies that test it; most in 2014 (6)

Studies that test 23-valent pneumococcal capsular polysaccharide vaccine, by start year
YearStudies
20001
20012
20031
20051
20074
20082
20101
20121
20131
20146
20154
20162
20181
20202
20216
20221
20231
20241
20261

By phase

A phase 1/2 study counts in both.

Early Phase 1
2
Phase 1
4
Phase 2
7
Phase 3
11
Phase 4
16
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 16 · Other 23

Merck Sharp & Dohme LLC (5) · GlaxoSmithKline (3) · Assistance Publique - Hôpitaux de Paris (2) · China National Biotec Group Company Limited (2) · CanSino Biologics Inc. (1) · Ab&B Bio-tech Co., Ltd.JS (1) · Universitaire Ziekenhuizen KU Leuven (1) · Mayo Clinic (1)

Often tested with

Tested in the same studies.

Pneumococcal Vaccines (21) · 13-valent pneumococcal vaccine (8) · Vi polysaccharide vaccine, typhoid (2) · Diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis -Haemophilus influenzae type b conjugate vaccine (1) · ASP3772 (1) · Intramuscular Route of Administration (1) · Meningococcal Vaccines (1) · Boostrix (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test 23-valent pneumococcal capsular polysaccharide vaccine.

Studies

Open first, then newest update. How each study uses 23-valent pneumococcal capsular polysaccharide vaccine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 39

See all 39 studies that test 23-valent pneumococcal capsular polysaccharide vaccine →

Given beside what is tested · 29 — 23-valent pneumococcal capsular polysaccharide vaccine is usual care or a partner of the new treatment

Showing 20 of 29.

As the comparator · 30 — what is tested is compared with 23-valent pneumococcal capsular polysaccharide vaccine

Showing 20 of 30.